ANDA 90718, held by Glenmark Pharmaceuticals. Hydrochlorothiazide; Moexipril Hydrochloride.
As of Nov 22, 2026, ANDA 90718 (Moexipril Hydrochloride and Hydrochlorothiazide), held by Glenmark Pharmaceuticals, was first approved by FDA on Mar 17, 2010, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 17, 2010 | Original application | Approved | None posted |
| Moexipril Hydrochloride and Hydrochlorothiazide12.5MG;7.5MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Discontinued |
| Moexipril Hydrochloride and Hydrochlorothiazide12.5MG;15MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Discontinued |
| Moexipril Hydrochloride and Hydrochlorothiazide25MG;15MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Discontinued |
| Aug 20, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 13, 2013 | Supplement 3Labeling | Approved | None posted |
| Dec 13, 2013 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 29, 2011 | Supplement 2Labeling | Approved | None posted |
| Jul 26, 2011 | Supplement 1Labeling | Approved | None posted |
| Mar 17, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters